Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury

MT Newswires Live

07/24

Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.

The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.

The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.

The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2653166706"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653166706\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653166706?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653166706","market":"hk","top_or_hot":-1,"title":"Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury","media":"MT Newswires Live","content":"<html><body><p> Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.</p><p>The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.</p><p>The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.</p><p>The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-24 13:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.</p><p>The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.</p><p>The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.</p><p>The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持倉","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653166706","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653166706","pubTimestamp":1784871689,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kringle Pharma  has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury , according to a Friday filing.The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4192":"特殊消费者服务","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","SCI":"Service Corp International","SCI.AU":"Silver City Minerals Ltd"},"translate_title":"Kringle Pharma 启动 Oremepermin Alfa 治疗急性脊髓损伤的额外三期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCI.AU":1,"SCI":1},"content_text":"Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}